127 related articles for article (PubMed ID: 37748560)
1. Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children.
Zapata-Cobo P; Salvador-Matín S; Velasco M; Palomino LM; Clemente S; Segarra O; Moreno-Álvarez A; Fernández-Lorenzo A; Pérez-Moneo B; Montraveta M; Sánchez C; Tolín M; Loverdos I; Fobelo MJ; Navas-López VM; Magallares L; García-Romero R; Sánchez-Hernández JG; Rodríguez A; Bossacoma F; Balboa MJ; Salcedo E; Sanjurjo-Sáez M; López-Fernández LA
Pharmacol Res; 2023 Oct; 196():106938. PubMed ID: 37748560
[No Abstract] [Full Text] [Related]
2. Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children.
Zapata-Cobo P; Salvador-Martín S; Velasco M; Palomino LM; Clemente S; Segarra O; Moreno-Álvarez A; Fernández-Lorenzo A; Pérez-Moneo B; Montraveta M; Sánchez C; Tolín M; Loverdos I; Fobelo MJ; Navas-López VM; Magallares L; García-Romero R; Sánchez-Hernández JG; Rodríguez A; Bossacoma F; Balboa MJ; Salcedo E; Sanjurjo-Sáez M; López-Fernández LA
Pharmacol Res; 2023 Aug; 194():106859. PubMed ID: 37473877
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of trough serum anti-TNF levels in paediatric inflammatory bowel disease.
Salvador-Martín S; Pujol-Muncunill G; Bossacoma F; Navas-López VM; Gallego-Fernández C; Segarra O; Clemente S; Muñoz-Codoceo R; Viada J; Magallares L; Martínez-Ojinaga E; Moreno-Álvarez A; Solar-Boga A; Loverdos I; Merino-Bohórquez V; Balboa-Vega MJ; Rodriguez-Martinez A; Alvarez-Vayo C; Sanchez C; Tolin M; Blanca-García JA; García-Romero R; Eizaguirre FJ; Sánchez-Hernandez JG; de Caldas RG; Millán-Jimenez A; Aznal E; Abarca-Zabalía J; Sanjurjo-Sáez M; López-Fernández LA
Br J Clin Pharmacol; 2021 Feb; 87(2):447-457. PubMed ID: 32478906
[TBL] [Abstract][Full Text] [Related]
4. Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort.
Salvador-Martín S; Zapata-Cobo P; Velasco M; Palomino LM; Clemente S; Segarra O; Sánchez C; Tolín M; Moreno-Álvarez A; Fernández-Lorenzo A; Pérez-Moneo B; Loverdos I; Navas López VM; Millán A; Magallares L; Torres-Peral R; García-Romero R; Pujol-Muncunill G; Merino-Bohorquez V; Rodríguez A; Salcedo E; López-Cauce B; Marín-Jiménez I; Menchén L; Laserna-Mendieta E; Lucendo AJ; Sanjurjo-Sáez M; López-Fernández LA
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675312
[TBL] [Abstract][Full Text] [Related]
5. Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease.
Prieto-Pérez R; Almoguera B; Cabaleiro T; Hakonarson H; Abad-Santos F
Int J Mol Sci; 2016 Feb; 17(2):225. PubMed ID: 26861312
[TBL] [Abstract][Full Text] [Related]
6. Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy.
Miler M; Nikolac Gabaj N; Ćelap I; Grazio S; Tomašić V; Bišćanin A; Mitrović J; Đerek L; Morović-Vergles J; Vrkić N; Štefanović M
Rheumatol Int; 2021 Dec; 41(12):2195-2203. PubMed ID: 34623480
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis.
Ovejero-Benito MC; Prieto-Pérez R; Llamas-Velasco M; Muñoz-Aceituno E; Reolid A; Saiz-Rodríguez M; Belmonte C; Román M; Ochoa D; Talegón M; Cabaleiro T; Daudén E; Abad-Santos F
Pharmacogenomics; 2018 Jan; 19(1):7-16. PubMed ID: 29192552
[TBL] [Abstract][Full Text] [Related]
8. Time to antibody detection and associated factors for presence of anti-drug antibodies in pediatric inflammatory bowel disease patients treated with anti-TNF therapy.
Moses J; Lambert-Jenkins K; Momotaz H; Sattar A; Debanne SM; Splawski J; Sferra TJ
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1228-1233. PubMed ID: 31498282
[TBL] [Abstract][Full Text] [Related]
9. Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.
Salvador-Martín S; Raposo-Gutiérrez I; Navas-López VM; Gallego-Fernández C; Moreno-Álvarez A; Solar-Boga A; Muñoz-Codoceo R; Magallares L; Martínez-Ojinaga E; Fobelo MJ; Millán-Jiménez A; Rodriguez-Martinez A; Vayo CA; Sánchez C; Tolin M; Bossacoma F; Pujol-Muncunill G; González de Caldas R; Loverdos I; Blanca-García JA; Segarra O; Eizaguirre FJ; García-Romero R; Merino-Bohórquez V; Sanjurjo-Sáez M; López-Fernández LA
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397546
[TBL] [Abstract][Full Text] [Related]
10. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
[TBL] [Abstract][Full Text] [Related]
11. Tumour necrosis factor (TNF) antagonist therapy for paediatric inflammatory bowel disease: A systematic review.
Martín-García P; Alonso-Arroyo A; Catalá-López F
Med Clin (Barc); 2023 Jun; 160(11):501-516. PubMed ID: 36967304
[TBL] [Abstract][Full Text] [Related]
12. Comment: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children.
Yii CY; Chiu HH; Yong SB
Pharmacol Res; 2023 Oct; 196():106937. PubMed ID: 37769888
[No Abstract] [Full Text] [Related]
13. Pharmacogenetics of inflammatory bowel disease.
Katsanos KH; Papadakis KA
Pharmacogenomics; 2014 Dec; 15(16):2049-62. PubMed ID: 25521361
[TBL] [Abstract][Full Text] [Related]
14. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
[TBL] [Abstract][Full Text] [Related]
15. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
Aardoom MA; Veereman G; de Ridder L
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
[TBL] [Abstract][Full Text] [Related]
16. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.
Julsgaard M; Christensen LA; Gibson PR; Gearry RB; Fallingborg J; Hvas CL; Bibby BM; Uldbjerg N; Connell WR; Rosella O; Grosen A; Brown SJ; Kjeldsen J; Wildt S; Svenningsen L; Sparrow MP; Walsh A; Connor SJ; Radford-Smith G; Lawrance IC; Andrews JM; Ellard K; Bell SJ
Gastroenterology; 2016 Jul; 151(1):110-9. PubMed ID: 27063728
[TBL] [Abstract][Full Text] [Related]
17. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
[TBL] [Abstract][Full Text] [Related]
18. Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.
Chanchlani N; Lin S; Auth MK; Lee CL; Robbins H; Looi S; Murugesan SV; Riley T; Preston C; Stephenson S; Cardozo W; Sonwalkar SA; Allah-Ditta M; Mansfield L; Durai D; Baker M; London I; London E; Gupta S; Di Mambro A; Murphy A; Gaynor E; Jones KDJ; Claridge A; Sebastian S; Ramachandran S; Selinger CP; Borg-Bartolo SP; Knight P; Sprakes MB; Burton J; Kane P; Lupton S; Fletcher A; Gaya DR; Colbert R; Seenan JP; MacDonald J; Lynch L; McLachlan I; Shields S; Hansen R; Gervais L; Jere M; Akhtar M; Black K; Henderson P; Russell RK; Lees CW; Derikx LAAP; Lockett M; Betteridge F; De Silva A; Hussenbux A; Beckly J; Bendall O; Hart JW; Thomas A; Hamilton B; Gordon C; Chee D; McDonald TJ; Nice R; Parkinson M; Gardner-Thorpe H; Butterworth JR; Javed A; Al-Shakhshir S; Yadagiri R; Maher S; Pollok RCG; Ng T; Appiahene P; Donovan F; Lok J; Chandy R; Jagdish R; Baig D; Mahmood Z; Marsh L; Moss A; Abdulgader A; Kitchin A; Walker GJ; George B; Lim YH; Gulliver J; Bloom S; Theaker H; Carlson S; Cummings JRF; Livingstone R; Beale A; Carter JO; Bell A; Coulter A; Snook J; Stone H; Kennedy NA; Goodhand JR; Ahmad T;
Aliment Pharmacol Ther; 2022 Oct; 56(8):1250-1263. PubMed ID: 36039036
[TBL] [Abstract][Full Text] [Related]
19. Utilization trends of anti-TNF agents and health outcomes in adults and children with inflammatory bowel diseases: a single-center experience.
Park KT; Sin A; Wu M; Bass D; Bhattacharya J
Inflamm Bowel Dis; 2014 Jul; 20(7):1242-9. PubMed ID: 24846718
[TBL] [Abstract][Full Text] [Related]
20. Differential Serum-intestinal Dynamics of Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.
Bar-Yoseph H; Blatt A; Gerassy S; Pressman S; Mousa A; Sabo E; Waterman M; Ungar B; Ben-Horin S; Chowers Y
J Crohns Colitis; 2022 Jul; 16(6):884-892. PubMed ID: 34849649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
